NDA 020314 · Curium
Octreoscan
Indium In-111 Pentetreotide Kit · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Jun 2, 1994
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
128
87 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 21, 2022.
INDICATIONS AND USAGE Octreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 2, 1994 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- OCTREOSCAN · INDIUM IN-111 PENTETREOTIDE KIT 3mCi/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Indium In-111 Pentetreotide Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- intentional drug misuse31
- death21
- haemoglobin abnormal16
- nausea15
- drug ineffective14
- platelet disorder10
- product use issue10
- disease progression8
- product use in unapproved indication8
- blood bilirubin abnormal7
- haematotoxicity7
- pyrexia7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 17 |
| 2010 | 37 |
| 2011 | 3 |
| 2012 | 4 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 8 |
| 2019 | 1 |
| 2020 | 21 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- PET imaging in ectopic Cushing syndrome: a systematic review.
Santhanam P, Taieb D, Giovanella L, et al. · Endocrine 2015 · Systematic Review
- Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis.
Jiang Y, Hou G, Cheng W · Nucl Med Commun 2020 · Meta-Analysis
- Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM, Cornelius E, Lawton GP · Arch Surg 1995 · Clinical Trial, Comparative Study
- 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.
Paganelli G, Sansovini M, Nicolini S, et al. · Eur J Nucl Med Mol Imaging 2021 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
Kahaly G, Diaz M, Just M, et al. · Thyroid 1995 · Clinical Trial
- (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
Sun H, Jiang XF, Wang S, et al. · Endocrine 2007 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.